Nylén Eric
Veterans Affairs Medical Center, George Washington University School of Medicine, Washington, DC 20422, USA.
Rev Cardiovasc Med. 2022 Aug 10;23(8):282. doi: 10.31083/j.rcm2308282. eCollection 2022 Aug.
A plethora of diabetes studies and established clinical guidelines show the strong salutary benefit of aerobic, resistance, and/or combination exercise for improved glycemic and cardiovascular outcomes. Promotion of physical fitness is a cornerstone approach to improved diabetes management especially since subjects with diabetes have reduced baseline aerobic exercise capacity (i.e., reduced cardiorespiratory fitness) with associated increased risk for premature all-cause and cardiovascular mortality. Since medications are often used in conjunction with fitness promotion this can result in complex interaction between management modalities. More recently, newer options such as glucose transporter-2 inhibitors and incretin agonists have shown to improve cardiovascular disease (CVD) outcomes in cardiovascular outcomes trials. Indeed, both classes of agents have experimentally the potential to synergize with exercise training but clinical data vis-à-vis cardiorespiratory fitness is still preliminary. Review of the interaction of exercise and metformin shows no improvement in cardiorespiratory fitness. The use of glucose transporter-2 inhibitors may improve fitness performance in those with diabetes and heart failure. Although incretin agonists have physiological effects on the vasculature and heart, they lack similar clinical supportive data.
大量糖尿病研究及既定临床指南表明,有氧运动、抗阻运动和/或联合运动对改善血糖和心血管结局具有显著益处。促进身体健康是改善糖尿病管理的基石方法,尤其是因为糖尿病患者的基线有氧运动能力降低(即心肺适能降低),全因过早死亡和心血管死亡风险相应增加。由于药物治疗通常与促进身体健康相结合,这可能导致管理方式之间产生复杂的相互作用。最近,葡萄糖转运蛋白2抑制剂和肠促胰岛素激动剂等新选择在心血管结局试验中已显示可改善心血管疾病(CVD)结局。事实上,这两类药物在实验上都有与运动训练协同作用的潜力,但关于心肺适能的临床数据仍处于初步阶段。对运动与二甲双胍相互作用的综述表明,心肺适能并无改善。使用葡萄糖转运蛋白2抑制剂可能会改善糖尿病合并心力衰竭患者的体能表现。尽管肠促胰岛素激动剂对血管系统和心脏有生理作用,但它们缺乏类似的临床支持数据。